GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radius Health Inc (NAS:RDUS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Radius Health (Radius Health) Cash, Cash Equivalents, Marketable Securities : $72.5 Mil (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Radius Health Cash, Cash Equivalents, Marketable Securities?

Radius Health's quarterly cash, cash equivalents, marketable securities declined from Dec. 2021 ($111.53 Mil) to Mar. 2022 ($71.62 Mil) but then increased from Mar. 2022 ($71.62 Mil) to Jun. 2022 ($72.49 Mil).

Radius Health's annual cash, cash equivalents, marketable securities declined from Dec. 2019 ($160.90 Mil) to Dec. 2020 ($114.72 Mil) and declined from Dec. 2020 ($114.72 Mil) to Dec. 2021 ($111.53 Mil).


Radius Health Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Radius Health's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radius Health Cash, Cash Equivalents, Marketable Securities Chart

Radius Health Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.28 236.46 160.90 114.72 111.53

Radius Health Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.17 109.56 111.53 71.62 72.49

Radius Health Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Radius Health  (NAS:RDUS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Radius Health Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Radius Health's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Radius Health (Radius Health) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radius Health Inc (NAS:RDUS) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Executives
Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jean Pierre Garnier director UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
G. Kelly Martin director, officer: CEO and President C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Sean Murphy director C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Elizabeth Messersmith officer: Senior Vice President 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Danielle Holtschlag officer: Vice President, Sales 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Chhaya Shah officer: Chief Business Officer 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Susan Vissers Lisa director 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000